The role of pharmaceutical care in diabetes management

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 6, 2005, Pages 352-356

  Davis, Timothy M E ^a   Clifford, Rhonda M ^b   Davis, Wendy A ^a   Batty, Kevin T ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

Diabetes; Pharmaceutical care; Vascular risk factors

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMMUNITY CARE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HIGH RISK PATIENT; HUMAN; INTERDISCIPLINARY COMMUNICATION; INTERVIEW; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; RISK REDUCTION; TEAMWORK; TELEPHONE;

EID: 30544452014     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050061001     Document Type: Article

References (22)

1. Strand LM, Cipolle RJ, Morley PC. Pharmaceutical care: an introduction. Kalamazoo, Michigan: Upjohn; 1992.
2. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
3. Knowlton CH, Thomas OV, Williamson A et al. Establishing community pharmacy-based anticoagulation education and monitoring programs. J Am Pharm Assoc 1999;39:368-74.
4. Kennie NR, Schuster BG, Einarson TR. Critical analysis of the pharmaceutical care research literature. Ann Pharmacother 1998;32:17-26.
5. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977;34:1238-42.
6. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36:1321-5.
7. Jaber LA, Halapy H, Fernet M, Turnmalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
8. Halapy H, Jaber LA. Diabetes management: follow-up. Ann Pharmacother 1997;31:371.
9. Coast-Senior E, Kroner B, Kelley C, Trilli L. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Am J Health Syst Pharm 1998;55:638-41.
10. Baran RW, Crumlish K, Patterson H et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counselling. Am J Health Syst Pharm 1999;56:1535-9.
11. Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm 2000;6:488-93.
12. Oclegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother 2005;39:433-40.
13. Cooper J. Consultant pharmacist contribution to diabetes mellitus patients outcomes in two nursing facilities. Consult Pharm 1995;10:40-5.
14. Veldhuizen-Scott M, Widmer L, Stacey F, Popovich N. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diab Educ 1995;21:117-23.
15. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team - a pilot study Pharm World Sci 2004;26:18-25.
16. Cranor C, Bunting B, Christensen D. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
17. Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-300.
18. Clifford RM, Batty KT, Davis TM et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract 2002;10:85-9.
19. Clifford RM, Batty KT, Davis WA, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005;28:771-6.
20. Davis TM, Zimmet F, Davis WA, Bruce D, Fida S, Mackay I. Autoantibodies to glutamic acid clecarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 2000;17:667-74.
21. Bruce DG, Davis WA, Davis TM. Glycemic control in elderly subjects with type 2 diabetes mellitus in the Fremantle Diabetes Study J Am Geriatr Soc 2000;48:1449-53.
22. Stevens RJ, Kothari V, Adler AI, Stratton IM for the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9.